PCSK9 antibodies: A new class of lipid-lowering drugs

Atherosclerosis Supplements

Volumn 18, Issue , 2015, Pages 21-27

  Gouni Berthold, Ioanna ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cardiovascular endpoints; LDL cholesterol; PCSK9 antibodies

Indexed keywords

ALIROCUMAB; ATORVASTATIN; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUTRALIZING ANTIBODY; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

ARTICLE; CARDIOVASCULAR RISK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LONG TERM CARE; MONOTHERAPY; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84928880926     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2015.02.003     Document Type: Article

References (30)

1. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U. S. A 2003, 100:928-933.
2. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
3. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
4. Cohen J.C., Hobbs H.H. Genetics. Simple genetics for a complex disease. Science 2013, 340:689-690.
5. Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 2014, 54:273-293.
6. Stein E.A., Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014, 65:417-431.
7. Farnier M. PCSK9 inhibitors. Curr Opin Lipidol 2013, 24:251-258.
8. Sullivan D., Olsson A.G., Scott R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308:2497-2506.
9. Koren M.J., Scott R., Kim J.B., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380:1995-2006.
10. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017.
11. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
12. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490.
13. Beliard S., Carreau V., Carrie A., et al. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis 2014, 234:136-141.
14. Marks D., Thorogood M., Neil H.A., Humphries S.E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003, 168:1-14.
15. Koren M.J., Giugliano R.P., Raal F.J., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014, 129:234-243.
16. Stein E.A., Giugliano R.P., Koren M.J., et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014, 35:2249-2259.
17. Desai N.R., Giugliano R.P., Zhou J., et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). J Am Coll Cardiol 2014, 63:430-433.
18. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012, 59:2344-2353.
19. Roth E.M., Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol 2014, 10:183-199.
20. Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380:29-36.
21. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012, 367:1891-1900.
22. Stroes E., Colquhoun D., Sullivan D., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014, 63:2541-2548.
23. Godlee F. Adverse effects of statins. Br Med J 2014, 348:g3306.
24. Koren M.J., Lundqvist P., Bolognese M., et al. Anti-PCSK9 monotherapy for hypercholesterolemia - the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014, 63:2531-2540.
25. Robinson J.G., Nedergaard B.S., Rogers W.J., et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014, 311:1870-1882.
26. Blom D.J., Hala T., Bolognese M., et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014, 370:1809-1819.
27. Stein E.A., Swergold G.D. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep 2013, 15:310.
28. Stein E., Stender S., Mata P., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004, 148:447-455.
29. Hooper A.J., Marais A.D., Tanyanyiwa D.M., Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193:445-448.
30. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.